

STABLE Performance Measures Summary

(*)National Quality Forum (NQF) Endorsed Dec. '06

Depression: Screening for bipolar mania/hypomania prior to treatment for depression (*)	This measure assesses the percentage of patients presenting with depression who were assessed, prior to the initiation of treatment, for the presence of prior or current symptoms and/or behaviors associated with mania or hypomania.
Depression or Bipolar Disorder: Assessment for risk of suicide (*)	This measure assesses the percentage of patients diagnosed with bipolar disorder, or with unipolar depression, who receive an initial assessment that considers the risk of suicide.
Depression or Bipolar Disorder: Assessment for substance use (*)	This measure assesses the percentage of patients with bipolar disorder, or unipolar depression, who receive an initial assessment that considers alcohol and chemical substance use.
Bipolar Disorder: Use of antimanic agent in BD I; mania/hypomania, mixed, or cycling	This measure assesses the percentage of patients with Bipolar I Disorder with mania/hypomania, mixed or cycling symptoms and behaviors who have evidence of use of a pharmacotherapy agent with antimanic properties during the first 12 weeks of treatment.
Bipolar Disorder: Use of a mood stabilizing or antimanic agent in BD I; depression	This measure assesses the percentage of patients with Bipolar I Disorder with depression symptoms and behaviors who have evidence of use of a mood stabilizing or antimanic agent during the first 12 weeks of treatment.
Bipolar Disorder: Avoidance of antidepressant monotherapy in BD I	This measure assesses the percentage of patients with Bipolar I Disorder who received monotherapy with an antidepressant agent during the first 12 weeks of treatment.
Bipolar Disorder: Monitoring for weight gain	This measure assesses the percentage of patients with bipolar disorder who were monitored for weight gain during the initial 12 weeks of treatment.
Bipolar Disorder: Monitoring for extrapyramidal symptoms	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with an antipsychotic agent who were assessed for the presence of extrapyramidal symptoms twice within the first 24 weeks of treatment.

STABLE Performance Measures Summary

(*)National Quality Forum (NQF) Endorsed Dec. '06

Bipolar Disorder: Monitoring lithium levels	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with lithium who have evidence of a lithium medication level within 12 weeks of beginning treatment.
Bipolar Disorder: Screening for hyperglycemia when atypical antipsychotic agent is prescribed (*)	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with an atypical antipsychotic agent who receive at least one screening for hyperglycemia within the initial 16 weeks of treatment.
Bipolar Disorder: Monitoring for hyperlipidemia when atypical antipsychotic agent is prescribed	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with an atypical antipsychotic agent who receive at least one assessment for hyperlipidemia within the initial 16 weeks of treatment.
Bipolar Disorder: Providing condition-specific education and information	This measure assesses the percentage of patients diagnosed and treated for bipolar disorder who are provided with education and information about their illness and treatment within the initial 12 weeks of treatment.
Bipolar Disorder: Monitoring change in symptom complex	This measure assesses the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their symptom complex within 12 weeks of initiating treatment.
Bipolar Disorder: Recommending adjunctive psychosocial interventions	This measure assesses the percentage of patients with bipolar disorder who receive a recommendation for an adjunctive psychosocial intervention, including evidence-based therapies, within 12 weeks of initiating treatment.
Bipolar Disorder: Monitoring change in level-of-functioning (*)	This measure assesses the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their level-of-functioning within 12 weeks of initiating treatment.